BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahadevan D, Chalasani P, Rensvold D, Kurtin S, Pretzinger C, Jolivet J, Ramanathan RK, Von Hoff DD, Weiss GJ. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2013;36:239-243. [PMID: 22441342 DOI: 10.1097/coc.0b013e3182467a13] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen M, Kang Y. Cancer fitness genes: emerging therapeutic targets for metastasis. Trends Cancer 2022:S2405-8033(22)00190-X. [PMID: 36184492 DOI: 10.1016/j.trecan.2022.08.007] [Reference Citation Analysis]
2 Dai H, Abdullah R, Wu X, Li F, Ma Y, Lu A, Zhang G. Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. Front Cell Dev Biol 2022;10:855474. [PMID: 35652096 DOI: 10.3389/fcell.2022.855474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Papaefthymiou A, Doukatas A, Galanopoulos M. Pancreatic cancer and oligonucleotide therapy: exploring novel therapeutic options and targeting chemoresistance. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee YM, Vucic D. Inhibitor of Apoptosis are Critical Signaling Mediators in Inflammation and Cancer. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00191-7] [Reference Citation Analysis]
5 Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, Ranieri E. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers (Basel) 2021;13:3949. [PMID: 34439105 DOI: 10.3390/cancers13163949] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
6 Galanopoulos M, Doukatas A, Gkeros F, Viazis N, Liatsos C. Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy. World J Gastroenterol 2021; 27(24): 3568-3580 [PMID: 34239270 DOI: 10.3748/wjg.v27.i24.3568] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Choi AY, Manook M, Olaso D, Ezekian B, Park J, Freischlag K, Jackson A, Knechtle S, Kwun J. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Front Immunol 2021;12:694763. [PMID: 34177960 DOI: 10.3389/fimmu.2021.694763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 He L, Sehrawat TS, Verma VK, Navarro-Corcuera A, Sidhu G, Mauer A, Luo X, Katsumi T, Chen J, Shah S, Arab JP, Cao S, Kashkar H, Gores GJ, Malhi H, Shah VH. XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. Front Physiol 2021;12:664222. [PMID: 34025452 DOI: 10.3389/fphys.2021.664222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tan ML, Sahul Hamid SB, Abduraman MA, Tan HK. Apoptosis and Cancer. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-30845-2_17] [Reference Citation Analysis]
10 Yamakawa K, Nakano-Narusawa Y, Hashimoto N, Yokohira M, Matsuda Y. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. Int J Mol Sci 2019;20:E4224. [PMID: 31470511 DOI: 10.3390/ijms20174224] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
11 Takakura K, Kawamura A, Torisu Y, Koido S, Yahagi N, Saruta M. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer. Int J Mol Sci 2019;20:E3331. [PMID: 31284594 DOI: 10.3390/ijms20133331] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
12 Jan R, Chaudhry GE. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Adv Pharm Bull 2019;9:205-18. [PMID: 31380246 DOI: 10.15171/apb.2019.024] [Cited by in Crossref: 205] [Cited by in F6Publishing: 225] [Article Influence: 68.3] [Reference Citation Analysis]
13 Cossu F, Milani M, Mastrangelo E, Lecis D. Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment. Comput Struct Biotechnol J 2019;17:142-50. [PMID: 30766663 DOI: 10.1016/j.csbj.2019.01.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
14 Sato-Dahlman M, Wirth K, Yamamoto M. Role of Gene Therapy in Pancreatic Cancer-A Review. Cancers (Basel). 2018;10. [PMID: 29614005 DOI: 10.3390/cancers10040103] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
15 Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 2017;22:898-919. [PMID: 28424988 DOI: 10.1007/s10495-017-1375-1] [Cited by in Crossref: 141] [Cited by in F6Publishing: 154] [Article Influence: 35.3] [Reference Citation Analysis]
16 Al Hasan A, Azam AZ. Small RNA-mediated prevention, diagnosis and therapies of cancer. Design of Nanostructures for Theranostics Applications 2018. [DOI: 10.1016/b978-0-12-813669-0.00009-9] [Reference Citation Analysis]
17 Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, Qadri Z, Ajarim D, Al-Dayel F, Beg S, Al-Kuraya KS. XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer 2017;17:640. [PMID: 28893228 DOI: 10.1186/s12885-017-3627-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
18 Prokop JW, Lazar J, Crapitto G, Smith DC, Worthey EA, Jacob HJ. Molecular modeling in the age of clinical genomics, the enterprise of the next generation. J Mol Model 2017;23:75. [PMID: 28204942 DOI: 10.1007/s00894-017-3258-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
19 Modi S, Kir D, Banerjee S, Saluja A. Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. J Cell Biochem. 2016;117:279-288. [PMID: 26206252 DOI: 10.1002/jcb.25284] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
20 Díaz Osterman CJ, Gonda A, Stiff T, Sigaran U, Valenzuela MM, Ferguson Bennit HR, Moyron RB, Khan S, Wall NR. Curcumin Induces Pancreatic Adenocarcinoma Cell Death Via Reduction of the Inhibitors of Apoptosis. Pancreas 2016;45:101-9. [PMID: 26348467 DOI: 10.1097/MPA.0000000000000411] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
21 Vorvis C, Koutsioumpa M, Iliopoulos D. Developments in miRNA gene signaling pathways in pancreatic cancer. Future Oncol. 2016;12:1135-1150. [PMID: 26984178 DOI: 10.2217/fon-2015-0050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
22 Chaudhary AK, Yadav N, Bhat TA, O'Malley J, Kumar S, Chandra D. A potential role of X-linked inhibitor of apoptosis protein in mitochondrial membrane permeabilization and its implication in cancer therapy. Drug Discov Today 2016;21:38-47. [PMID: 26232549 DOI: 10.1016/j.drudis.2015.07.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
23 Mu GG, Zhang LL, Li HY, Liao Y, Yu HG. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. Dig Dis Sci. 2015;60:1067-1080. [PMID: 25344906 DOI: 10.1007/s10620-014-3394-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
24 Xiong S, Mu T, Wang G, Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell 2014;5:737-49. [PMID: 25073422 DOI: 10.1007/s13238-014-0089-1] [Cited by in Crossref: 239] [Cited by in F6Publishing: 223] [Article Influence: 29.9] [Reference Citation Analysis]
25 Stintzing S, Lenz HJ. Molecular pathways: turning proteasomal protein degradation into a unique treatment approach. Clin Cancer Res 2014;20:3064-70. [PMID: 24756373 DOI: 10.1158/1078-0432.CCR-13-3175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
26 Khan S, Ansarullah , Kumar D, Jaggi M, Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res. 2013;73:6541-6547. [PMID: 24204026 DOI: 10.1158/0008-5472.can-13-1288] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
27 Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther 2013;9:1285-304. [PMID: 24092992 DOI: 10.2147/OTT.S33375] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 9.4] [Reference Citation Analysis]
28 Owens TW, Gilmore AP, Streuli CH, Foster FM. Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy. J Carcinog Mutagen 2013;Suppl 14:S14-004. [PMID: 25328816 DOI: 10.4172/2157-2518.S14-004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]